Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan J Darrow

Showing results (41-50 of 82) with videos related to

Pageof 9
Sort By:
Journal of Health Politics, Policy and Law|March 30, 2023
Trust and Regulation: Assuring Scientific Independence in the FDA's Emergency Use Authorization ProcessNeeraj G Patel, Aaron S Kesselheim, Jonathan J Darrow
American Journal of Public Health|September 9, 2020
Drug Shortages and the Defense Production ActBrooke L Raunig, Aaron S Kesselheim, Jonathan J Darrow
The New England Journal of Medicine|January 15, 2015
Practical, legal, and ethical issues in expanded access to investigational drugsJonathan J Darrow, Ameet Sarpatwari, Jerry Avorn, et al.
Pharmacoepidemiology and Drug Safety|August 17, 2020
Understanding when real world data can be used to replicate a clinical trial: A cross-sectional study of medications approved in 2011Michael Fralick, Emily Bartsch, Jonathan J Darrow, et al.
The Lancet. Infectious Diseases|June 6, 2020
Regulatory approval characteristics of antimicrobial versus non-antimicrobial products, 1984-2018: an evaluation of Food and Drug Administration flexibilitiesJonathan J Darrow, Mehdi Najafzadeh, Kristina Stefanini, et al.
The New England Journal of Medicine|December 21, 2017
The Regulatory Accountability Act of 2017 - Implications for FDA Regulation and Public HealthJonathan J Darrow, Erin C Fuse Brown, Aaron S Kesselheim
Journal of Global Oncology|December 21, 2019
Expanding Coverage of Oncology Drugs in an Aging, Upper-Middle-Income Country: Analyses of Public and Private Expenditures in ChileVeronica Vargas, Christine Leopold, Marianela Castillo-Riquelme, et al.
Science Translational Medicine|November 12, 2020
Efficacy and costs of spinal muscular atrophy drugsJonathan J Darrow, Monica Sharma, Mansa Shroff, et al.
Health Affairs (Project Hope)|October 8, 2014
Existing FDA pathways have potential to ensure early access to, and appropriate use of, specialty drugsAaron S Kesselheim, Yongtian Tina Tan, Jonathan J Darrow, et al.
Journal of Law and the Biosciences|January 29, 2024
CRISPR-phage antibacterials to address the antibiotic resistance crisis: scientific, economic, and regulatory considerationsDanielle M Pacia, Beatrice L Brown, Timo Minssen, et al.
Pageof 9

Showing results (41-50 of 82) with videos related to

Sort By:
Pageof 9
Journal of Health Politics, Policy and Law|March 30, 2023
Trust and Regulation: Assuring Scientific Independence in the FDA's Emergency Use Authorization ProcessNeeraj G Patel, Aaron S Kesselheim, Jonathan J Darrow
American Journal of Public Health|September 9, 2020
Drug Shortages and the Defense Production ActBrooke L Raunig, Aaron S Kesselheim, Jonathan J Darrow
The New England Journal of Medicine|January 15, 2015
Practical, legal, and ethical issues in expanded access to investigational drugsJonathan J Darrow, Ameet Sarpatwari, Jerry Avorn, et al.
Pharmacoepidemiology and Drug Safety|August 17, 2020
Understanding when real world data can be used to replicate a clinical trial: A cross-sectional study of medications approved in 2011Michael Fralick, Emily Bartsch, Jonathan J Darrow, et al.
The Lancet. Infectious Diseases|June 6, 2020
Regulatory approval characteristics of antimicrobial versus non-antimicrobial products, 1984-2018: an evaluation of Food and Drug Administration flexibilitiesJonathan J Darrow, Mehdi Najafzadeh, Kristina Stefanini, et al.
The New England Journal of Medicine|December 21, 2017
The Regulatory Accountability Act of 2017 - Implications for FDA Regulation and Public HealthJonathan J Darrow, Erin C Fuse Brown, Aaron S Kesselheim
Journal of Global Oncology|December 21, 2019
Expanding Coverage of Oncology Drugs in an Aging, Upper-Middle-Income Country: Analyses of Public and Private Expenditures in ChileVeronica Vargas, Christine Leopold, Marianela Castillo-Riquelme, et al.
Science Translational Medicine|November 12, 2020
Efficacy and costs of spinal muscular atrophy drugsJonathan J Darrow, Monica Sharma, Mansa Shroff, et al.
Health Affairs (Project Hope)|October 8, 2014
Existing FDA pathways have potential to ensure early access to, and appropriate use of, specialty drugsAaron S Kesselheim, Yongtian Tina Tan, Jonathan J Darrow, et al.
Journal of Law and the Biosciences|January 29, 2024
CRISPR-phage antibacterials to address the antibiotic resistance crisis: scientific, economic, and regulatory considerationsDanielle M Pacia, Beatrice L Brown, Timo Minssen, et al.
Pageof 9